Literature DB >> 31520409

Preemptively Precise: Returning and Updating Pharmacogenetic Test Results to Realize the Benefits of Preemptive Testing.

Cyrine E Haidar1, Mary V Relling1, James M Hoffman1,2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31520409      PMCID： PMC6777995          DOI： 10.1002/cpt.1613

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  5 in total

1.  PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics.

Authors:  James M Hoffman; Cyrine E Haidar; Mark R Wilkinson; Kristine R Crews; Donald K Baker; Nancy M Kornegay; Wenjian Yang; Ching-Hon Pui; Ulrike M Reiss; Aditya H Gaur; Scott C Howard; William E Evans; Ulrich Broeckel; Mary V Relling
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-03-11       Impact factor: 3.908

2.  Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.

Authors:  Philip E Empey; James M Stevenson; Sony Tuteja; Kristin W Weitzel; Dominick J Angiolillo; Amber L Beitelshees; James C Coons; Julio D Duarte; Francesco Franchi; Linda J B Jeng; Julie A Johnson; Rolf P Kreutz; Nita A Limdi; Kristin A Maloney; Aniwaa Owusu Obeng; Josh F Peterson; Natasha Petry; Victoria M Pratt; Fabiana Rollini; Stuart A Scott; Todd C Skaar; Mark R Vesely; George A Stouffer; Russell A Wilke; Larisa H Cavallari; Craig R Lee
Journal:  Clin Pharmacol Ther       Date:  2018-01-30       Impact factor: 6.875

3.  Patient re-contact after revision of genomic test results: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Karen L David; Robert G Best; Leslie Manace Brenman; Lynn Bush; Joshua L Deignan; David Flannery; Jodi D Hoffman; Ingrid Holm; David T Miller; James O'Leary; Reed E Pyeritz
Journal:  Genet Med       Date:  2018-12-22       Impact factor: 8.822

4.  Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.

Authors:  S L Van Driest; Y Shi; E A Bowton; J S Schildcrout; J F Peterson; J Pulley; J C Denny; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2013-11-19       Impact factor: 6.875

5.  Recontacting patients in clinical genetics services: recommendations of the European Society of Human Genetics.

Authors:  Daniele Carrieri; Heidi C Howard; Caroline Benjamin; Angus J Clarke; Sandi Dheensa; Shane Doheny; Naomi Hawkins; Tanya F Halbersma-Konings; Leigh Jackson; Hülya Kayserili; Susan E Kelly; Anneke M Lucassen; Álvaro Mendes; Emmanuelle Rial-Sebbag; Vigdís Stefánsdóttir; Peter D Turnpenny; Carla G van El; Irene M van Langen; Martina C Cornel; Francesca Forzano
Journal:  Eur J Hum Genet       Date:  2018-10-11       Impact factor: 4.246
  5 in total
  7 in total

Review 1.  Advancing Pharmacogenomics from Single-Gene to Preemptive Testing.

Authors:  Cyrine E Haidar; Kristine R Crews; James M Hoffman; Mary V Relling; Kelly E Caudle
Journal:  Annu Rev Genomics Hum Genet       Date:  2022-05-10       Impact factor: 9.340

Review 2.  Pediatric pharmacogenomics: challenges and opportunities: on behalf of the Sanford Children's Genomic Medicine Consortium.

Authors:  David Gregornik; Daria Salyakina; Marilyn Brown; Samuel Roiko; Kenneth Ramos
Journal:  Pharmacogenomics J       Date:  2020-08-26       Impact factor: 3.550

3.  Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.

Authors:  Ina Liko; Yee Ming Lee; Danielle L Stutzman; Allison B Blackmer; Kimberly M Deininger; Ann M Reynolds; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2021-03-04       Impact factor: 2.533

4.  The Value of Pharmacogenetics to Reduce Drug-Related Toxicity in Cancer Patients.

Authors:  Doreen Z Mhandire; Andrew K L Goey
Journal:  Mol Diagn Ther       Date:  2022-02-03       Impact factor: 4.074

5.  Characterizing pharmacogenetic programs using the consolidated framework for implementation research: A structured scoping review.

Authors:  John H McDermott; Stuart Wright; Videha Sharma; William G Newman; Katherine Payne; Paul Wilson
Journal:  Front Med (Lausanne)       Date:  2022-08-18

Review 6.  Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example.

Authors:  David F Kisor; Natasha J Petry; David R Bright
Journal:  Pharmgenomics Pers Med       Date:  2021-05-18

7.  Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection.

Authors:  Amber L Beitelshees; James M Stevenson; Nihal El Rouby; Chrisly Dillon; Philip E Empey; Elliot M Fielstein; Julie A Johnson; Nita A Limdi; Henry H Ong; Francesco Franchi; Dominick J Angiolillo; Joshua F Peterson; Marc B Rosenman; Todd C Skaar; Sony Tuteja; Larisa H Cavallari
Journal:  Genet Med       Date:  2020-07-17       Impact factor: 8.864
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.